Clinical and baseline characteristics according to the DNMT3A mutational status and according to the DNMT3A/NPM1/FLT3-ITD mutations
| Characteristics . | All patients, no. (%) . | DNMT3A mutated, no. (%) . | DNMT3A nonmutated, no. (%) . | P* . | Triple-mutated, no. (%) . | Non–triple-mutated, no. (%) . | P* . |
|---|---|---|---|---|---|---|---|
| Age, y | <.001† | .003† | |||||
| 18-40 | 157 (31) | 6 (9.4) | 151 (34.1) | 3 (8.6) | 154 (32.6) | ||
| 41-60 | 185 (36.5) | 34 (53.1) | 151 (34.1) | 21 (60) | 164 (34.7) | ||
| 60 and older | 165 (32.5) | 24 (37.5) | 141 (31.8) | 11 (31.4) | 154 (32.6) | ||
| Median (range) | 50.6 (18, 93.8) | 54.4 (27, 91) | 49.2 (18, 93.8) | .003† | 54.8 (27, 77.5) | 49.9 (18, 93.8) | .08 |
| Sex | .033† | .292 | |||||
| Female | 269 (53.1) | 42 (66.6) | 227 (51.2) | 22 (62.9) | 247 (52.3) | ||
| Male | 238 (46.9) | 22 (34.4) | 216 (48.8) | 13 (37.1) | 225 (47.7) | ||
| FAB subtype | .756 | .928 | |||||
| M0 | 22 (4.7) | 2 (3.4) | 20 (4.9) | 1 (3.1) | 21 (4.8) | ||
| M1 | 90 (19.3) | 9 (15.3) | 81 (19.9) | 7 (21.9) | 83 (19.1) | ||
| M2 | 150 (32.1) | 17 (28.8) | 133 (32.6) | 12 (37.5) | 138 (31.7) | ||
| M4 | 150 (32.1) | 23 (39) | 127 (31.1) | 10 (31.3) | 140 (32.2) | ||
| M5 | 41 (8.8) | 7 (11.9) | 34 (8.3) | 2 | 39 (9) | ||
| M6 | 10 (2.1) | 1 (1.7) | 9 (2.2) | 10 (2.3) | |||
| M7 | 4 (0.9) | 4 (1) | 4 (0.9) | ||||
| Missing data | 40 | 5 | 35 | 3 | 37 | ||
| Cytogenetic risk stratification‡ | <.001† | .006† | |||||
| Favorable | 69 (19.5) | 69 (22.6) | 69 (21.1) | ||||
| Intermediate | 227 (64.3) | 43 (89.6) | 184 (60.3) | 24 (92.3) | 203 (62.1) | ||
| Adverse | 57 (16.1) | 5 (10.4) | 52 (17) | 2 (7.7) | 55 (16.8) | ||
| Missing data§ | 154 | 16 | 138 | 145 | |||
| FLT3-ITD | <.001† | ||||||
| Mutated | 134 (26.4) | 42 (65.6) | 94 (20.8) | ||||
| Nonmutated | 373 (73.1) | 22 (34.4) | 351 (79.2) | ||||
| NPM1 | <.001† | ||||||
| Mutated | 145 (28.6) | 44 (68.8) | 103 (22.8) | ||||
| Nonmutated | 362 (71.4) | 20 (31.3) | 342 (77.2) | ||||
| BM blasts, median (range), % | 67 (20, 100) | 74 (20, 96) | 66 (10, 100) | .143 | 77 (21, 96) | 66 (20, 100) | .117 |
| Leukocyte count, median (range), ×109/L | 27.3 (0.28, 790) | 61 (0.28, 435) | 25.6 (0.6, 790) | .009† | 67 (0.86, 435) | 26 (0.28, 790) | .001† |
| Platelet count, median (range), ×109/L | 45 (3, 600) | 59 (5, 404) | 44 (3, 600) | .818 | 60 (10, 196) | 45 (3, 600) | .763 |
| Hg, median (range), g/dL | 8.1 (3, 16.2) | 8 (3.1, 11.6) | 8.1 (3, 16.2) | .727 | 7.8 (3.9, 13.2) | 8.1 (3, 16.2) | .534 |
| LDH level, median (range), U/I | 682.5 (116, 11 722) | 775 (136, 5289) | 662 (116, 11 722) | .188 | 767 (136, 2789) | 672 (116, 11 722) | .607 |
| Complete remission, % | 60 | 53 | 60 | .786 | 62 | 59 | .725 |
| OS, % (95% CI) | 20 (16, 24) | 9 (3, 18) | 22 (17, 27) | .003† | 3 (0-14) | 22 (17, 26) | .011† |
| DFS, % (95% CI) | 38 (31, 45) | 19 (7, 34) | 42 (34, 49) | <.001† | 4 (0-19) | 42 (35, 50) | <.001† |
| CIR, % (95% CI) | 54 (48, 60) | 72 (58, 86) | 50 (42, 57) | <.001† | 85 (71, 98) | 50 (43, 56) | <.001† |
| Characteristics . | All patients, no. (%) . | DNMT3A mutated, no. (%) . | DNMT3A nonmutated, no. (%) . | P* . | Triple-mutated, no. (%) . | Non–triple-mutated, no. (%) . | P* . |
|---|---|---|---|---|---|---|---|
| Age, y | <.001† | .003† | |||||
| 18-40 | 157 (31) | 6 (9.4) | 151 (34.1) | 3 (8.6) | 154 (32.6) | ||
| 41-60 | 185 (36.5) | 34 (53.1) | 151 (34.1) | 21 (60) | 164 (34.7) | ||
| 60 and older | 165 (32.5) | 24 (37.5) | 141 (31.8) | 11 (31.4) | 154 (32.6) | ||
| Median (range) | 50.6 (18, 93.8) | 54.4 (27, 91) | 49.2 (18, 93.8) | .003† | 54.8 (27, 77.5) | 49.9 (18, 93.8) | .08 |
| Sex | .033† | .292 | |||||
| Female | 269 (53.1) | 42 (66.6) | 227 (51.2) | 22 (62.9) | 247 (52.3) | ||
| Male | 238 (46.9) | 22 (34.4) | 216 (48.8) | 13 (37.1) | 225 (47.7) | ||
| FAB subtype | .756 | .928 | |||||
| M0 | 22 (4.7) | 2 (3.4) | 20 (4.9) | 1 (3.1) | 21 (4.8) | ||
| M1 | 90 (19.3) | 9 (15.3) | 81 (19.9) | 7 (21.9) | 83 (19.1) | ||
| M2 | 150 (32.1) | 17 (28.8) | 133 (32.6) | 12 (37.5) | 138 (31.7) | ||
| M4 | 150 (32.1) | 23 (39) | 127 (31.1) | 10 (31.3) | 140 (32.2) | ||
| M5 | 41 (8.8) | 7 (11.9) | 34 (8.3) | 2 | 39 (9) | ||
| M6 | 10 (2.1) | 1 (1.7) | 9 (2.2) | 10 (2.3) | |||
| M7 | 4 (0.9) | 4 (1) | 4 (0.9) | ||||
| Missing data | 40 | 5 | 35 | 3 | 37 | ||
| Cytogenetic risk stratification‡ | <.001† | .006† | |||||
| Favorable | 69 (19.5) | 69 (22.6) | 69 (21.1) | ||||
| Intermediate | 227 (64.3) | 43 (89.6) | 184 (60.3) | 24 (92.3) | 203 (62.1) | ||
| Adverse | 57 (16.1) | 5 (10.4) | 52 (17) | 2 (7.7) | 55 (16.8) | ||
| Missing data§ | 154 | 16 | 138 | 145 | |||
| FLT3-ITD | <.001† | ||||||
| Mutated | 134 (26.4) | 42 (65.6) | 94 (20.8) | ||||
| Nonmutated | 373 (73.1) | 22 (34.4) | 351 (79.2) | ||||
| NPM1 | <.001† | ||||||
| Mutated | 145 (28.6) | 44 (68.8) | 103 (22.8) | ||||
| Nonmutated | 362 (71.4) | 20 (31.3) | 342 (77.2) | ||||
| BM blasts, median (range), % | 67 (20, 100) | 74 (20, 96) | 66 (10, 100) | .143 | 77 (21, 96) | 66 (20, 100) | .117 |
| Leukocyte count, median (range), ×109/L | 27.3 (0.28, 790) | 61 (0.28, 435) | 25.6 (0.6, 790) | .009† | 67 (0.86, 435) | 26 (0.28, 790) | .001† |
| Platelet count, median (range), ×109/L | 45 (3, 600) | 59 (5, 404) | 44 (3, 600) | .818 | 60 (10, 196) | 45 (3, 600) | .763 |
| Hg, median (range), g/dL | 8.1 (3, 16.2) | 8 (3.1, 11.6) | 8.1 (3, 16.2) | .727 | 7.8 (3.9, 13.2) | 8.1 (3, 16.2) | .534 |
| LDH level, median (range), U/I | 682.5 (116, 11 722) | 775 (136, 5289) | 662 (116, 11 722) | .188 | 767 (136, 2789) | 672 (116, 11 722) | .607 |
| Complete remission, % | 60 | 53 | 60 | .786 | 62 | 59 | .725 |
| OS, % (95% CI) | 20 (16, 24) | 9 (3, 18) | 22 (17, 27) | .003† | 3 (0-14) | 22 (17, 26) | .011† |
| DFS, % (95% CI) | 38 (31, 45) | 19 (7, 34) | 42 (34, 49) | <.001† | 4 (0-19) | 42 (35, 50) | <.001† |
| CIR, % (95% CI) | 54 (48, 60) | 72 (58, 86) | 50 (42, 57) | <.001† | 85 (71, 98) | 50 (43, 56) | <.001† |
Values are shown as number (percentage), unless otherwise specified in the row headings as median (range) or percentage (95% CI).
BM, bone marrow; CIR, cumulative incidence of relapse; DFS, disease-free survival; FAB, French-American-British; Hg, hemoglobin; LDH, lactate dehydrogenase; OS, overall survival
Missing values were excluded for the calculation of P values.
Indicates statistically significant differences.
The cytogenetic risk groups were defined according to Medical Research Council criteria.24
Material not available or no metaphases detected.